Recent research highlights a persistent challenge in Canada's healthcare system: significant delays in accessing new pharmaceuticals compared to international peers. A comprehensive study published by the Fraser Institute in early 2026 reveals that Canadian patients endure waits of more than 65 weeks longer than Europeans and over 90 weeks—equivalent to roughly 21 months—longer than Americans for approval and availability of innovative new drugs. This gap underscores broader issues in the drug approval process managed by Health Canada, the federal agency responsible for regulating pharmaceuticals to ensure safety, efficacy, and quality.

The study, titled Timely Access to New Pharmaceuticals in Canada, the United States, and European Union—2026, analyzes data from fiscal years 2019/20 to 2024/25, examining 194 drugs approved in both Canada and the United States, as well as comparisons with the European Medicines Agency (EMA). These delays not only limit patient options but also contribute to poorer health outcomes and elevated system costs, as patients rely on older, less effective treatments longer.

🔬 Key Findings from the Fraser Institute Analysis

The research meticulously tracks approval timelines from submission to market availability, distinguishing between regulatory review times and manufacturer submission delays. For the 194 matched drugs, the U.S. Food and Drug Administration (FDA) approved medicines an average of 636 days before Health Canada—a stark illustration of the lag. When focusing solely on review periods for drugs submitted simultaneously, Health Canada still trails the FDA, particularly for standard reviews not qualifying for priority pathways.

• Average total lag vs. U.S.: Over 90 weeks.
• Average lag vs. EU: More than 65 weeks.
• 145 drugs approved by FDA and EMA between 2019 and 2025 remain unapproved in Canada.

These figures build on prior Fraser Institute reports, showing a consistent pattern over decades, though recent reforms have shown marginal improvements in priority review categories like oncology drugs.

Dissecting the Timelines: Submission vs. Review Delays

Health Canada's New Drug Submission (NDS) process involves a rigorous evaluation of clinical trials, manufacturing standards, and risk-benefit profiles. Drugs can enter via standard (up to 300 days target) or priority review (target 180 days) for serious conditions. However, the study identifies two primary bottlenecks:

1. Submission Delays: Pharmaceutical companies often file NDS applications to Health Canada 12-18 months after U.S. or EU submissions. This strategic choice stems from Canada's smaller market—about 38 million people versus 330 million in the U.S.—making it lower priority amid global launch sequences.
2. Review Delays: Even when filed concurrently, Health Canada's standard review averages longer than FDA's, though priority paths are competitive.

Data drawn from recent international comparisons. Notably, orphan drugs for rare diseases and oncology therapies show variable performance, with Canada lagging most in non-urgent categories.

💊 Drugs Unavailable in Canada: A Growing Concern

One of the study's most alarming revelations is that 145 innovative therapies greenlit by the FDA and EMA have yet to reach Canadian patients. These include treatments for rare genetic disorders, advanced cancers, and chronic conditions where timely intervention is critical. The absence stems from manufacturers opting not to pursue Canadian approval, citing regulatory hurdles and uncertain reimbursement.

For instance, while specific drug names from the 2026 dataset are aggregated for analysis, historical parallels include delays in CAR-T cell therapies for leukemia, where U.S. patients gained access years earlier, improving survival rates significantly. This "not-in-Canada" phenomenon exacerbates inequities, particularly for patients in remote provinces reliant on national pharmacare negotiations.

Root Causes: Pricing Controls and Market Dynamics

Pharmaceutical firms prioritize larger markets like the U.S., where higher prices recoup research and development (R&D) costs—estimated at $2.6 billion per new drug globally. Canada's Patented Medicine Prices Review Board (PMPRB), which caps prices based on international references, recently reformed in 2025, but lingering uncertainty deters filings. Additional factors include:

• Provincial reimbursement variability, delaying post-approval access.
• Smaller clinical trial pools, complicating local data requirements.
• Intellectual property concerns amid aggressive generics entry.

Stakeholders from research positions in health economics note that these incentives create a vicious cycle: delayed access reduces R&D investment in Canada, further shrinking the market.

🚨 Real-World Patient Impacts

The human cost is profound. Delayed access means patients endure suboptimal therapies, leading to disease progression, reduced quality of life, and higher mortality. A 2024 analysis of oncology delays estimated thousands of life-years lost annually in Canada. For rare diseases, where patient numbers are few, waits can exceed three years, forcing cross-border travel or compassionate access pleas.

Consider non-small cell lung cancer (NSCLC) immunotherapies: U.S. approvals in 2021 translated to Canadian availability by 2023-2024, during which progression-free survival gaps widened. Stories abound of families crowdfunding U.S. treatments, highlighting systemic failures in equitable care under Canada's universal model.

Cancer and Rare Diseases: Hardest Hit Areas

Oncology drugs, despite priority status, face average lags of 12-18 months. Rare disease therapies suffer most, with orphan designations not fully mitigating submission hesitancy. University-led research from institutions like the University of Toronto underscores how these delays inflate healthcare expenditures—hospitalizations and palliative care costs soar without timely biologics.

• Cancer: 48,000+ potential progression-free life years lost.
• Rare diseases: Limited trials amplify approval scrutiny.
• Overall: Poorer survival metrics vs. peers.

📢 Stakeholder Perspectives

Patient advocacy groups like the Canadian Organization for Rare Disorders decry the lags as life-threatening. Pharma Canada echoes the Fraser findings, urging streamlined processes without compromising safety. Health Canada defends its rigor, pointing to post-market surveillance strengths, but critics argue agility is needed. Academics in health policy careers advocate balanced reforms.

The Fraser authors recommend incentives for early submissions, PMPRB modernization, and harmonization with FDA/EMA.

Government Responses and Reforms

In response to such critiques, Health Canada launched a December 2025 consultation on the Ministerial Reliance Order, allowing partial reliance on FDA/EMA decisions for select drugs. This could slash review times by deeming certain modules complete, with feedback due February 28, 2026. Critics, including university experts, warn of over-reliance risks without robust Canadian data. View the Gazette proposal.

Photo by Philip Yu on Unsplash

🔮 Future Outlook and Actionable Solutions

Optimism surrounds 2026 reforms, potentially aligning Canada closer to peers. Policymakers could:

• Implement filing incentives via tax credits for research assistants in trials.
• Enhance priority pathways for high-impact drugs.
• Foster public-private partnerships for R&D, boosting university involvement.

Long-term, integrating real-world evidence could expedite post-approval monitoring. Patients benefit most from urgency—advocate via petitions and engage in consultations.

In summary, the Fraser Institute's 2026 publication spotlights a solvable crisis. Explore higher ed jobs in health research, rate professors at Rate My Professor, or seek career advice in pharma policy. For opportunities, visit university jobs or post a job.